Supplementary Table. Baseline Demographic and Disease Characteristics of Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) Study Participants — United States and International Sites, 2021–2022

Details

• Alternative Title:
  Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022: Supplementary Table. Baseline Demographic and Disease Characteristics of Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) Study Participants — United States and International Sites, 2021–2022
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 51
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  2 pdf page
• Volume:
  72
• Issue:
  51
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:33ad10014d4d8f57eda9caa556634f3f6a2beec90e9295bb0fb00ab2e18e95c2081489fb4771ff0e58da264c05040bfa83f84baee5f50ae7b7973b060c366a34
• Download URL:
  https://stacks.cdc.gov/view/cdc/136166/cdc_136166_DS1.pdf
• File Type:
  [PDF - 200.40 KB ]